Headlines about Epizyme (NASDAQ:EPZM) have been trending somewhat positive on Friday, according to Accern Sentiment. The research group identifies negative and positive news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Epizyme earned a media sentiment score of 0.21 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 46.3242340042134 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Several brokerages recently weighed in on EPZM. BidaskClub raised Epizyme from a “strong sell” rating to a “sell” rating in a research note on Tuesday. Oppenheimer reaffirmed a “buy” rating and set a $26.00 target price on shares of Epizyme in a research note on Tuesday, September 19th. Zacks Investment Research raised Epizyme from a “hold” rating to a “buy” rating and set a $20.00 target price for the company in a research note on Monday, October 16th. Jefferies Group began coverage on Epizyme in a research note on Wednesday, September 20th. They set a “buy” rating and a $23.00 target price for the company. Finally, Cann reaffirmed a “buy” rating and set a $26.00 target price on shares of Epizyme in a research note on Tuesday, September 19th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and ten have assigned a buy rating to the company’s stock. Epizyme currently has a consensus rating of “Buy” and a consensus price target of $22.67.
Epizyme (NASDAQ EPZM) opened at $13.00 on Friday. Epizyme has a 1 year low of $9.30 and a 1 year high of $20.45.
In related news, insider Peter Tai-Ching Ho sold 15,000 shares of the stock in a transaction dated Monday, September 25th. The stock was sold at an average price of $16.81, for a total value of $252,150.00. Following the completion of the sale, the insider now directly owns 23,123 shares of the company’s stock, valued at approximately $388,697.63. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director David M. Mott acquired 200,000 shares of Epizyme stock in a transaction that occurred on Monday, September 18th. The stock was acquired at an average cost of $15.25 per share, with a total value of $3,050,000.00. Following the completion of the purchase, the director now owns 6,000 shares in the company, valued at approximately $91,500. The disclosure for this purchase can be found here. 25.20% of the stock is currently owned by corporate insiders.
WARNING: “Epizyme (EPZM) Earning Somewhat Positive Press Coverage, Analysis Finds” was originally posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at https://www.chaffeybreeze.com/2017/12/08/epizyme-epzm-earning-somewhat-positive-press-coverage-analysis-finds.html.
Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).
Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with MarketBeat.com's FREE daily email newsletter.